Absci (NASDAQ:ABSI) Given New $15.00 Price Target at Needham & Company LLC

Absci (NASDAQ:ABSI) had its target price hoisted by investment analysts at Needham & Company LLC from $11.00 to $15.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC‘s target price indicates a potential upside of 64.11% from the stock’s current price.

Other analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating on shares of Absci in a research report on Tuesday, October 20th. Jefferies Financial Group started coverage on shares of Absci in a research note on Thursday, October 29th. They issued a “buy” rating and a $14.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on shares of Absci from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Guggenheim reissued a “buy” rating on shares of Absci in a research report on Monday, September 28th. Finally, KeyCorp increased their target price on shares of Absci from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Absci has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Absci Price Performance

Shares of Absci stock opened at $9.14 on Thursday. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -11.43 and a beta of 2.22. The stock has a 50-day simple moving average of $9.66 and a 200-day simple moving average of $6.78. Absci has a 52-week low of $2.24 and a 52-week high of $12.54.

Absci (NASDAQ:ABSI) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.66 million. Absci had a negative return on equity of 61.71% and a negative net margin of 7,756.38%. As a group, equities research analysts predict that Absci will post -0.76 earnings per share for the current year.

Institutional Trading of Absci

A number of institutional investors and hedge funds have recently modified their holdings of ABSI. BlackRock Inc. bought a new stake in shares of Absci during the 2nd quarter worth $141,112,000. Siren L.L.C. bought a new position in Absci in the 1st quarter worth $5,400,000. Parkman Healthcare Partners LLC acquired a new position in Absci during the 2nd quarter worth $10,366,000. Bank of America Corp DE acquired a new position in Absci during the 2nd quarter worth $6,560,000. Finally, Artia Global Partners LP bought a new stake in Absci during the second quarter valued at about $5,383,000. 52.05% of the stock is currently owned by institutional investors and hedge funds.

Absci News Roundup

These are some of the ABSI news items that stood out recently:

• Positive Sentiment: Absci said its ABS-201 HEADLINE trial for pattern hair loss remains on track, with 13-week interim proof-of-concept data expected in December 2026 and full 26-week results anticipated in early 2027. Those results are a key near-term catalyst. Article: Absci Q3 2026: December hair-loss data is the only number that matters
• Neutral Sentiment: Absci appointed Gerry Muhle, a former executive at Galderma, Allergan and GSK, as chief commercial officer. The hire adds commercialization experience, though its impact will depend on progress in the pipeline. Article: Absci Appoints Gerry Muhle as Chief Commercial Officer
• Negative Sentiment: Quarterly revenue was $0.3 million, below the cited $0.66 million consensus estimate, while net loss widened to $33.3 million from $28.7 million a year earlier. The reported $0.19 loss per share met one consensus estimate, although another source said it missed its estimate—adding to the mixed earnings read-through. Article: Absci Reports Q3 Loss, Misses Revenue Estimates

Absci Company Profile

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.